Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981810096> ?p ?o ?g. }
- W2981810096 endingPage "100009" @default.
- W2981810096 startingPage "100009" @default.
- W2981810096 abstract "New blood vessels formation from the existing vasculature is called angiogenesis. It is an essential physiological process for the growth of cells, tissue repair, wound healing, and reproductive system of females. The process of angiogenesis regulation is related to diseases such as rheumatism arthritis, diabetes, atherosclerosis, and cancer. The growth and metastasis of the tumor is directly depend on the process of tumor angiogenesis. Tumor angiogenesis is regulated by the proangiogenic factors and anti-angiogenic factors formed by the host cells as well as the tumor cells. Among various growth factors, namely VEGFs, PDGFs, FGFs, and cytokines; VEGFs and its receptor VEGFR-2 (KDR) have a significant impact on the process of angiogenesis. After the activation initiated, KDR undergoes autophosphorylation that ultimately leads to a proliferation of the endothelial cells, tumor angiogenesis, tumor growth, and metastasis. VEGFR-2 overexpression is observed in different kinds of cancer, namely breast cancer, cervical cancer, non-small cell lung cancer, hepatocellular carcinoma, renal carcinoma, and likewise. Over the past decade, several VEGFR-2 inhibitors have been developed. Angiogenesis inhibition by blocking the VEGFR-2 is an emerging strategy to develop selective and specific anticancer agents. The review articles published before were based on the structure and biology of VEGFR-2 rather than medicinal chemistry. While the emphasis of the current review article is to summarise, the recent advancement regarding VEGFR-2 inhibitors concerning medicinal chemistry approaches." @default.
- W2981810096 created "2019-11-01" @default.
- W2981810096 creator A5050245398 @default.
- W2981810096 creator A5069931740 @default.
- W2981810096 date "2019-06-01" @default.
- W2981810096 modified "2023-10-16" @default.
- W2981810096 title "Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective" @default.
- W2981810096 cites W1416958482 @default.
- W2981810096 cites W1422195457 @default.
- W2981810096 cites W1494565731 @default.
- W2981810096 cites W1595998158 @default.
- W2981810096 cites W1628621745 @default.
- W2981810096 cites W1639582946 @default.
- W2981810096 cites W1824408582 @default.
- W2981810096 cites W1875150791 @default.
- W2981810096 cites W1966885459 @default.
- W2981810096 cites W1966931906 @default.
- W2981810096 cites W1967600348 @default.
- W2981810096 cites W1972317743 @default.
- W2981810096 cites W1973262582 @default.
- W2981810096 cites W1973662262 @default.
- W2981810096 cites W1973701758 @default.
- W2981810096 cites W1974218564 @default.
- W2981810096 cites W1975223905 @default.
- W2981810096 cites W1977999028 @default.
- W2981810096 cites W1980813769 @default.
- W2981810096 cites W1982478414 @default.
- W2981810096 cites W1983064145 @default.
- W2981810096 cites W1984226397 @default.
- W2981810096 cites W1985043086 @default.
- W2981810096 cites W1985167734 @default.
- W2981810096 cites W1985712533 @default.
- W2981810096 cites W1992101966 @default.
- W2981810096 cites W1992945955 @default.
- W2981810096 cites W1993011693 @default.
- W2981810096 cites W1993225078 @default.
- W2981810096 cites W1993675254 @default.
- W2981810096 cites W1994072496 @default.
- W2981810096 cites W1996671618 @default.
- W2981810096 cites W1998763573 @default.
- W2981810096 cites W1999745763 @default.
- W2981810096 cites W2000064849 @default.
- W2981810096 cites W2000390423 @default.
- W2981810096 cites W2001035837 @default.
- W2981810096 cites W2001658518 @default.
- W2981810096 cites W2002359419 @default.
- W2981810096 cites W2004131152 @default.
- W2981810096 cites W2004239325 @default.
- W2981810096 cites W2006067741 @default.
- W2981810096 cites W2009222632 @default.
- W2981810096 cites W2011887296 @default.
- W2981810096 cites W2013670427 @default.
- W2981810096 cites W2014329705 @default.
- W2981810096 cites W2015344488 @default.
- W2981810096 cites W2017530822 @default.
- W2981810096 cites W2018512891 @default.
- W2981810096 cites W2018711732 @default.
- W2981810096 cites W2019061836 @default.
- W2981810096 cites W2020293198 @default.
- W2981810096 cites W2020709543 @default.
- W2981810096 cites W2021580214 @default.
- W2981810096 cites W2023453327 @default.
- W2981810096 cites W2024447293 @default.
- W2981810096 cites W2024956352 @default.
- W2981810096 cites W2027514622 @default.
- W2981810096 cites W2028160054 @default.
- W2981810096 cites W2028794212 @default.
- W2981810096 cites W2030205108 @default.
- W2981810096 cites W2030537668 @default.
- W2981810096 cites W2031061373 @default.
- W2981810096 cites W2033285233 @default.
- W2981810096 cites W2035387891 @default.
- W2981810096 cites W2039103451 @default.
- W2981810096 cites W2039589738 @default.
- W2981810096 cites W2041320722 @default.
- W2981810096 cites W2043103956 @default.
- W2981810096 cites W2045756126 @default.
- W2981810096 cites W2045958907 @default.
- W2981810096 cites W2046525214 @default.
- W2981810096 cites W2047352105 @default.
- W2981810096 cites W2049612319 @default.
- W2981810096 cites W2053221827 @default.
- W2981810096 cites W2055265038 @default.
- W2981810096 cites W2055701360 @default.
- W2981810096 cites W2059732801 @default.
- W2981810096 cites W2063170214 @default.
- W2981810096 cites W2063202257 @default.
- W2981810096 cites W2063978238 @default.
- W2981810096 cites W2064360454 @default.
- W2981810096 cites W2065272192 @default.
- W2981810096 cites W2068562114 @default.
- W2981810096 cites W2068955281 @default.
- W2981810096 cites W2069258346 @default.
- W2981810096 cites W2069823650 @default.
- W2981810096 cites W2071015683 @default.
- W2981810096 cites W2071638327 @default.
- W2981810096 cites W2077029264 @default.
- W2981810096 cites W2079398727 @default.